<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Daniel Geraghty | Brian D. Williamson, PhD</title>
    <link>https://bdwilliamson.github.io/author/daniel-geraghty/</link>
      <atom:link href="https://bdwilliamson.github.io/author/daniel-geraghty/index.xml" rel="self" type="application/rss+xml" />
    <description>Daniel Geraghty</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2014--2020 Brian D. Williamson</copyright><lastBuildDate>Mon, 07 Oct 2019 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://bdwilliamson.github.io/images/icon_huca44d5504774c48bc693dc9fda57798d_24945_512x512_fill_lanczos_center_2.png</url>
      <title>Daniel Geraghty</title>
      <link>https://bdwilliamson.github.io/author/daniel-geraghty/</link>
    </image>
    
    <item>
      <title>Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk</title>
      <link>https://bdwilliamson.github.io/publication/journal-article/hvtn-505/</link>
      <pubDate>Mon, 07 Oct 2019 00:00:00 +0000</pubDate>
      <guid>https://bdwilliamson.github.io/publication/journal-article/hvtn-505/</guid>
      <description>&lt;p&gt;While we do not yet have a broadly efficacious vaccine against HIV-1,
clinical trials of HIV-1 vaccine candidates can identify potential
correlates of risk or of protection. These correlates are measurable
signs that a person is at risk of or is protected from infection by
HIV-1, respectively. In this work, I collaborated with Peter Gilbert and
others affiliated with the 
&lt;a href=&#34;https://www.hvtn.org/en.html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;HIV Vaccine Trials
Network&lt;/a&gt; to analyze data from the 
&lt;a href=&#34;https://www.hvtn.org/en/community/community-compass/vol19-issue1/hvtn-505-recap.html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;HVTN
505&lt;/a&gt;
clinical trial. We identified three antibody features that inversely
correlated with HIV-1 infection risk. This may help in designing future
HIV-1 vaccines.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
